Armata Pharmaceuticals Inc., a clinical-stage biotechnology company specializing in bacteriophage therapeutics, announced that it will be featured in a key opinion leader webinar on November 25, 2025, focusing on Staphylococcus aureus (S. aureus) bacteremia and its investigational phage therapy, AP-SA02. The company previously presented positive results from its diSArm study at IDWeek 2025. The diSArm study was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability, and efficacy of intravenous AP-SA02 in combination with best available antibiotic therapy (BAT) versus BAT alone in adults with complicated S. aureus bacteremia. Results indicated that the combination of AP-SA02 and BAT achieved higher and earlier cure rates compared to BAT alone, with AP-SA02 showing a 100% response rate without relapse at key follow-up points, while the placebo group exhibited an approximate 25% relapse or lack of response. AP-SA02 was reported to be well-tolerated and demonstrated efficacy against both methicillin-resistant and methicillin-sensitive S. aureus.